Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu(Shandong University of Traditional Chinese Medicine), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom))
Cited by 121
Related Papers
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases
|Cell Death Discovery|2021|725
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
|The Oncologist|2007|418
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|379
Myo1b Promotes Premature Endothelial Senescence and Dysfunction via Suppressing Autophagy: Implications for Vascular Aging
|Oxidative Medicine and Cellular Longevity|2023|9